GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
530
c/glp1eu·posted 10 days ago by u/dario_petrescu

[Country] SE/NO/DK — Norway is the outlier and not in a good way

Country Clean Column ×8

SE/NO/DK — Norway is the outlier and not in a good way. It is the sort of thing everyone half-believes and nobody writes down.

Cross-border prescription recognition exists under EU rules but is conditional and narrower than commonly assumed, with requirements about the prescription’s form and content.

Pack sizes and presentations differ between member states, so a headline price is not comparable until it is normalised to a common quantity.

Pharmacy margins and dispensing fees are regulated nationally, which explains price differences that otherwise look arbitrary.

That is everything I have. The rest is opinion and I have tried to keep it out.

544 up / 14 down98% upvoted25 commentsid 14u3yp19 Jul 2026

25 comments

25 in this archive, depth 5

best — the order this archive was captured in

u/cardio_endpoint_c36 points·9 days ago·edited

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

replysharereportpermalink
[deleted]26 points·9 days ago

[deleted]

replysharereportpermalink
u/mikkel_correia13 points·9 days ago

EU-wide advice is almost always wrong somewhere

replysharereportpermalink
u/patient_labslip_log7 points·9 days ago

the language barrier is a real cost and nobody budgets for it

replysharereportpermalink
u/jarno_karlsen2 points·9 days ago·edited

Kept the prescription and the receipt for a claim, purely because a thread here told me to. Both were requested.

replysharereportpermalink
load more comments (1) →
u/mei_cardoso20 points·9 days ago

Same. Naming the country in the first line would fix most of the bad advice on this board.

replysharereportpermalink
u/pavel_kimani13 points·9 days ago

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

replysharereportpermalink
u/dario_petrescuOP11 points·9 days ago

The variation between pharmacies inside my own country was larger than the variation I had been chasing across the border.

replysharereportpermalink
u/vomit_free_since19 points·9 days ago·edited

Push back: comparing headline prices across countries without normalising pack size is comparing two different quantities.

replysharereportpermalink
u/dario_petrescuOP12 points·9 days ago

Is this a cross-border question or a domestic one?

replysharereportpermalink
u/cato_batista10 points·9 days ago

the reimbursement criteria are published in most member states

replysharereportpermalink
u/spain_receta3 points·9 days ago

Have you read the published reimbursement criteria where you are?

replysharereportpermalink
u/honest_syringe_maybe1 point·8 days ago

reimbursement is national, not European, and that is the whole board

replysharereportpermalink
u/dose_diary_danalog keeper1 point·8 days ago

Apotheke pricing and pharmacy pricing elsewhere are different systems

replysharereportpermalink
u/cesar_oyelaran4 points·9 days ago

Yes. Pack sizes differ enough that per-month price comparisons across borders need to be normalised before they mean anything.

replysharereportpermalink
u/dario_petrescuOP3 points·8 days ago

Correcting myself upthread: the criterion I quoted was updated for this year.

replysharereportpermalink
u/jarno_karlsen10 points·9 days ago

Assumed a prescription would be honoured across the border. It was not, and the rules are clear once you actually read them.

replysharereportpermalink
u/spain_recetaMOD5 points·10 days ago

Pharmacy link removed. No links of any kind here, in any country, for any reason.

replysharereportpermalink
u/oskar_malinowski6 points·10 days ago

Disagree. That is one member state’s reimbursement rule and it does not generalise across the union.

replysharereportpermalink
load more comments (1) →
u/eu_apotheke_a4 points·10 days ago

The structure that makes this board make sense, once.

Marketing authorisation for these products is granted centrally, which is why the same product exists across the union. Everything after that — whether it is reimbursed, on what criteria, at what price, in what pack size, dispensed under what margin rules — is decided nationally.

So "is it covered" has twenty-seven answers, "what does it cost" has twenty-seven answers plus within-country variation, and only "is it authorised" has one. Almost every argument on this board is two people answering different questions from different countries, both correctly.

replysharereportpermalink
u/ahmed_fonseca2 points·9 days ago·edited

The structure that makes this board make sense, once.

Agreed — and normalising pack size before comparing prices is the fix for half these threads.

replysharereportpermalink
u/signe_villalobos1 point·9 days ago

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

replysharereportpermalink
u/amara_haddad2 points·9 days ago

private pricing varies enormously between neighbouring countries

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/glp1eu

European access, country by country: prescription routes, reimbursement reality, pharmacy stock, EMA notices and the fact that "EU rules" is usually a national question wearing a European hat.

32kmembers
62submissions
Apr 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/glp1eu rules
  1. Tag your country in the title. Bare "EU" questions get a template reply.
  2. Pricing posts need the date and the currency.
  3. EMA and national agency claims need a citation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.